Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...

The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time ...

The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to ...

Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, Novo is shuttering its cell ...

The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer ...

CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...